Payment overview · 2025
General Payments
$666.32
31 reported records · 15 companies
Healthcare provider profile · identity verified
Sonya Miles
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WILLIAMSPORT, PA · NPI 1023461043
Verified facts
What the public records show
CMS Open Payments records show Sonya Miles received $666.32 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.23 | 16.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.38 | 15.1% | 4 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $86.45 | 13.0% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $66.47 | 10.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.34 | 8.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.88 | 6.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.51 | 5.9% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $37.94 | 5.7% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $25.17 | 3.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.04 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.78 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.51 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.68 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.42 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.52 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.32 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $97.68 | 5 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $86.45 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $66.47 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $57.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.06 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 286 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 68 |
| Gabapentin | Gabapentin | 264 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 38 |
| Lisinopril | Lisinopril | 199 | 47 |
| Omeprazole | Omeprazole | 156 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 35 |
| Losartan Potassium | Losartan Potassium | 119 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 23 |
| Famotidine | Famotidine | 111 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 18 |
| Furosemide | Furosemide | 91 | 22 |
| Mirtazapine | Mirtazapine | 91 | 12 |
| Trazodone Hcl | Trazodone Hcl | 90 | 22 |
| Metformin Hcl | Metformin Hcl | 88 | 29 |
| Ozempic | Semaglutide | 88 | 12 |
| Eliquis | Apixaban | 78 | 15 |
| Potassium Chloride | Potassium Chloride | 74 | 16 |
| Clonidine Hcl | Clonidine Hcl | 66 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 19 |
| Buspirone Hcl | Buspirone Hcl | 65 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 15 |
| Celecoxib | Celecoxib | 60 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Jardiance | Empagliflozin | 57 | 16 |
| Trulicity | Dulaglutide | 56 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Carvedilol | Carvedilol | 53 | 12 |
| Metformin Hcl Er | Metformin Hcl | 53 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | suppressed |
| Meloxicam | Meloxicam | 51 | 12 |
| Sertraline Hcl | Sertraline Hcl | 50 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 15 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 15 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 17 |
| Tramadol Hcl | Tramadol Hcl | 31 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Prednisone | Prednisone | 21 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.32 · 31 records | Novo Nordisk Inc | BREZTRI, CAPLYTA, CRYSVITA, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, M-M-R II, Omnipod, Ozempic, PROLIA, PROQUAD, QULIPTA, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VARIVAX, VIVITROL, VOQUEZNA, VRAYLAR, Wegovy, t:slim X2 Insulin Pump with Control-IQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error